IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Airline meal Camping food Combat Capabilities Development Command Soldier Center – prime developer of the MRE Individual Meal Pack – Canadian equivalent to the MRE List of military food topics Lunchables Meal kit Military chocolate Ninja diet Space food
==== MeSH D08.244.453 – cytochrome p-450 enzyme system ==== MeSH D08.244.453.040 – aryl hydrocarbon hydroxylases MeSH D08.244.453.040.050 – aniline hydroxylase MeSH D08.244.453.040.110 – benzopyrene hydroxylase MeSH D08.244.453.040.555 – cytochrome p-450 cyp1a1 MeSH D08.244.453.040.777 – cytochrome p-450 cyp1a2 MeSH D08.244.453.040.888 – cytochrome p-450 cyp2b1 MeSH D08.244.453.040.944 – cytochrome p-450 cyp2d6 MeSH D08.244.453.040.972 – cytochrome p-450 cyp2e1 MeSH D08.244.453.040.986 – cytochrome p-450 cyp3a MeSH D08.244.453.085 – camphor 5-monooxygenase MeSH D08.244.453.915 – steroid hydroxylases MeSH D08.244.453.915.050 – aldosterone synthase MeSH D08.244.453.915.099 – aromatase MeSH D08.244.453.915.200 – cholesterol 7 alpha-hydroxylase MeSH D08.244.453.915.212 – cholesterol side-chain cleavage enzyme MeSH D08.244.453.915.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.244.453.915.720 – steroid 11-beta-hydroxylase MeSH D08.244.453.915.730 – steroid 12-alpha-hydroxylase MeSH D08.244.453.915.737 – steroid 16-alpha-hydroxylase MeSH D08.244.453.915.748 – steroid 17-alpha-hydroxylase MeSH D08.244.453.915.760 – steroid 21-hydroxylase MeSH D08.244.453.957 – trans-cinnamate 4-monooxygenase
Lord Norton, a former Oxford classmate of Charles’, tells Yasmin he always knew Charles to be a sexual predator going back to his Oxford days. Later, Yasmin hires Alondra—the woman from the yacht—who implies Charles abused girls as young as twelve and gently suggests Yasmin may have been a victim as well, causing Yasmin to break down. At the end of series 4, Yasmin, who has herself become a predatory figure by trafficking escorts to powerful men, repeatedly listens to Charles' final voicemail inviting her on the boat trip.
== Political activity == Shawn has written many plays with socialist themes; much of his work examines the "connective tissue between private psychology and the politics of inequality". He identifies as a socialist in the 2011 essay "Why I Call Myself a Socialist: Is the World Really a Stage?", which was published online and later in his Essays. In June 2013, Shawn and many other public figures appeared in a video showing support for Chelsea Manning, a U.S. Army soldier imprisoned for leaking classified material.
Sources: en.wikipedia.org
Chet Faliszek (; born 1965) is an American video game writer who has worked for companies like Valve and Bossa Studios, having been involved in the story writing for series such as Half-Life, Portal, and Left 4 Dead.
=== Neurological and neurodegenerative disorders === There has been extensive research into the potential neuroprotective effects of metformin in developmental and neurodegenerative diseases, including Alzheimer's disease and other dementias, Parkinson's disease, Huntington's disease, certain types of epilepsy, and fragile X syndrome, with mixed results. Preliminary studies have examined whether metformin can reduce the risk of Alzheimer's disease and whether there is a correlation between type 2 diabetes and the risk of Alzheimer's disease. While metformin may reduce body weight in persons with fragile X syndrome, whether it improves neurological or psychiatric symptoms is uncertain.
==== Synthetic analogues ==== Synthetic analogues and derivatives, typically developed for research or therapeutic purposes, include altinicline, 6-chloronicotine, dianicline, levamisole, RJR-2429, TC-1698, UB-165, GTS-21, and varenicline, among others.
== Sustainability == The effects of climate change are becoming more of a concern for organizations, and mitigation strategies are being sought by the research community. While many laboratories are used to perform research to find innovative solutions to this global challenge, sustainable working practices in the labs are also contributing factors towards a greener environment. Many labs, such as those at the Massacusetts Institute of Technology and the University of Edinburgh, are already trying to minimize their environmental impact by reducing energy consumption, recycling, and implementing waste sorting processes to ensure correct disposal. Research labs featuring energy-intensive equipment use up to three to five times more energy per square meter than office areas. Major contributors to this high energy consumption are fume hoods. Fume hoods put a significant load on a buildings heating and cooling systems, as they remove high volumes of conditioned air from a lab when in use. Sensors, automatic shutoff systems, and awareness campaigns to close the sash window on fume hoods have been used to decrease the energy consumption of these devices. Normally, ultra-low temperature freezers are kept at −80 °C (−112 °F). One such device can consume up to the same amount of energy as a single-family household does in a day (25 kWh). Increasing the temperature to −70 °C (−94 °F) makes it possible to use 40% less energy and still keep most samples safely stored.
In 1988, Colin Pitchfork was the first person convicted of murder with DNA evidence, which led to the growth of forensic science. More recently, Andrew Z. Fire and Craig C. Mello received the 2006 Nobel Prize for discovering the role of RNA interference (RNAi) in the silencing of gene expression.
Sources: en.wikipedia.org
==== Metabolism ==== The metabolism of oxycodone in humans occurs in the liver mainly via the cytochrome P450 system and is extensive (about 95%) and complex, with many minor pathways and resulting metabolites. Around 10% (range 8–14%) of a dose of oxycodone is excreted essentially unchanged (unconjugated or conjugated) in the urine. The major metabolites of oxycodone are noroxycodone (70%), noroxymorphone ("relatively high concentrations"), and oxymorphone (5%). The immediate metabolism of oxycodone in humans is as follows:
Gastrointestinal system: nausea, vomiting, abdominal pain, and diarrhea Central nervous system: headache Whole body: fever, phlebitis or thrombophlebitis, complications at the intravenous cannulation site (e.g. induration), unspecified pain, flu-like syndrome, myalgia, chills, and paresthesia Respiratory: dyspnea Renal: increased plasma creatinine Hematological: anemia Electrolytes: hypokalemia Liver: increased liver enzymes (asymptomatic) Hypersensitivity: rash, facial edema, pruritus Other: tachycardia Additionally, infrequent cases of symptomatic liver damage, peripheral edema and swelling, and hypercalcemia have been seen.
===== Teleost fish ===== Like non-placental vertebrates, teleost fish also possess 5-HT cells in other sections of the brain, including the basal forebrain. Danio rerio (zebra fish) are a species of teleost fish often used for studying serotonin within the brain. Despite much being unknown about serotonergic systems in vertebrates, the importance in moderating stress and social interaction is known. It is hypothesized that AVT and CRF cooperate with serotonin in the hypothalamic-pituitary-interrenal axis. These neuropeptides influence the plasticity of the teleost, affecting its ability to change and respond to its environment. Subordinate fish in social settings show a drastic increase in 5-HT concentrations. High levels of 5-HT long term influence the inhibition of aggression in subordinate fish.
=== Cyst stage === To endure harsh environmental conditions, trophozoites transform into microbial cysts, spherical, single-layered structures about 7–15 μm in diameter, enclosing a single cell nucleus. Acting as a resilient capsule, the cyst enables the amoeba to withstand adverse circumstances. Factors triggering cyst formation include food scarcity, overcrowding, desiccation, waste accumulation, and cold temperatures. When conditions improve, the amoeba can emerge through the pore or ostiole at the center of the cyst. N. fowleri has been observed to encyst at temperatures below 10 °C (50 °F).
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.